HIMSS
To address Europe’s most pressing healthcare challenges, Europe's longest-running, most influential digital health conference returns in 2024, bringing together innovators to shape tomorrow’s healthcare.
The HIMSS24 European Health Conference & Exhibition will occur from 29-31 May at the Centro Congressi Roma La Nuvola in Rome, Italy. The conference will be the epicenter for pan-European collaborations and innovation, featuring thought leaders and healthcare professionals working together to create the best technology solutions across the digital health landscape.
HIMSS24 Europe will feature programming focused on major global health challenges. Experts will lead discussions on how Europe uses data analytics, artificial intelligence, cybersecurity, and other cutting-edge technologies to address universal issues like health equity, patient privacy, access to care, workforce burnout, staffing shortages, and climate change.
Registration is open for HIMSS24 Europe, and interested journalists can contact HIMSS to receive complimentary press credentials. The conference will attract thousands of industry experts worldwide, including CIOs and CTOs, AI experts, cybersecurity leaders, data scientists, healthcare practitioners, and public health policy leaders.
“We’ve built an innovative programme that offers the tools and insights healthcare professionals need to transform systems and improve outcomes,” said Ronan O’Connor, Managing Director, EMEA and Vice President at HIMSS. “This year, we are proud to bring executives, policymakers, and healthcare professionals of all kinds together in Italy, which is a leader in digital health innovation.”
The program lineup includes a deep dive into Europe’s current regulatory landscape, including the AI Act, the European Health Data Space (EHDS), and the European Recovery and Resilience Fund. This year’s keynote speakers will lend their expertise to enrich discussions on pressing healthcare issues.
- Marco Marsella, director, Digital, EU4Health and Health Systems Modernisation and DG SANTE, European Commission.
- Hela Ghariani, co-head of the Digital Health Delegation, Ministry of Social Affairs and Health, France and co-chair of the EU eHealth Network.
- John Riggi, FBI veteran and national advisor for cybersecurity and risk at the American Hospital Association
- Sharon Allen, co-founder and chief executive officer of World Telehealth Initiative, a remote philanthropic model that allows physicians to provide sustainable medical expertise via telehealth.
- Dr. Waheed Arian, founder of Arian Wellbeing.
Emerging topics such as the ethical use of AI in healthcare and finding the balance between effective data sharing and protecting patient privacy will be top of mind for presenters and attendees.
The conference will showcase emerging healthcare solutions through Startup Pitchfest, offering a platform for innovative startups to address entrenched challenges faced by health systems and providers.
The conference programming is supported by a Programme Committee comprising 17 highly reputable and well-respected healthcare professionals from across Europe.
Networking opportunities and interactive experiences will also be at the forefront of HIMSS24 Europe, where attendees can connect with representatives from more than 70 countries representing the global health ecosystem.
Click here to learn more about HIMSS24 Europe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424984367/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Launches RG660QA and RG660QB 5G Modules With Advanced Performance Features7.1.2026 18:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announces the launch of the RG600QA and RG660QB 5G module, based on the Qualcomm® X85 and X82 5G Modem-RF Systems. The RG660QA is based on X85 while the RG660QB is based onX82. Engineering samples of two first SKUs in the RG660Qx series have been already made available to customers and pre-production samples will be available to the market in Q2 2026. Designed for versatility, this module series supports a broad array of next generation 5G use cases, from home and business wireless broadband to mobile video, camera applications, and high-performance mobile hotspots. In indoor 5G CPE, it unlocks premium performance by enabling Wi-Fi 7 across the 2.4 GHz, 5 GHz, and 6 GHz bands, with integrated Bluetooth to support a full ecosystem of connected devices. With Ethernet speeds reaching up to 10 Gbps, the RG660Qx delivers the high-capacity backbone needed to power ultra-fast, reliable home and enterprise networks.
Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release
Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom